3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | Boehringer Ingelheim | 211 | 2019-03-19 | 2026-01-27 |
| ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors ⁸⁹Zr-Df-IAB22M2C - Positron-Emission Tomography, Metastatic Solid Tumors | Phase 2 | Completed | ImaginAb, Inc. | 52 | 2018-12-18 | 2024-07-09 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Mogamulizumab (KW-0761) - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2014-10-01 | 2021-04-23 |
Neoplasms (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
mogamulizumab (1)
Boehringer Ingelheim (1) · ImaginAb, Inc. (1) · Memorial Sloan Kettering Cancer Center (1)
United States (3) · Canada (1) · United Kingdom (1)
Jedd Wolchok, MD, PhD (1) · Ron Korn, MD, PhD (1)
2018 (1)